Centauri raised £30M in a Series A round announced on February 24, 2026. immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas.
immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas.
Centauri, based in London, United Kingdom, announced £30M in Series A financing on February 24, 2026.
Participants include The AMR Action Fund.
the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis.
a TechBio company focused on transforming clinical trials through artificial intelligence.
a platform that enables employees to build compliant enterprise software without writing code.